# A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

> **NCT05267600** · PHASE2,PHASE3 · COMPLETED · sponsor: **argenx** · enrollment: 98 (actual)

## Conditions studied

- Bullous Pemphigoid

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC
- **OTHER:** placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05267600
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-09-13
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267600, "A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05267600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*